London, United Kingdom · Founded 2020 · Privately Held (backing)
Developer of kidney-targeted gene therapy products intended for the treatment of chronic glomerular kidney diseases, including rare inherited and non-genetic conditions. Purespring Therapeutics is based in London, United Kingdom and was founded in 2020. Its last known valuation is $81.6 million. It has raised $165 million.
Last price · $/share
—
Implied valuation
$81.6M
Total raised
$164.7M
Last round
—
Team — not yet on record
No current team members for Purespring Therapeutics are on record yet. People surface from round filings, company disclosures, and coverage sessions.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Purespring Therapeutics with a free account
·Watch Purespring Therapeutics: the Monday email on marks, rounds and moves
